// App-Quantinova.ai

4565 : Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma.

Researchers

Presenter

  • Guru P. Sonpavde

Principal Investigators

  • Matt D. Galsky

  • Phoebe Wright

  • Zsolt Hepp

  • Nancy N. Chang

  • Candice Willmon

  • Steven Sesterhenn

  • Yutong Liu

  • Alicia K. Morgans

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Tisch Cancer Institute at Mount Sinai, New York, NY

  • Seagen, Inc., Bothell, WA

  • Dendreon Pharmaceuticals, Inc., Seattle, WA

  • Seattle Genetics, Bothell, WA

  • Astellas Pharma, Inc., Northbrook, IL

  • Genesis Research, Hoboken, NJ

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • Dendreon Pharmaceuti

  • Astellas Pharma Inc.

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Cisplatin

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved